Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Primary Immune Thrombocytopenia (VAYHIT1)
NCT05653349Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in primary immune thrombocytopenia (ITP) (3 arms), sponsored by Novartis. Primary endpoint: Rate of Stable Response off treatment at 12 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05653349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653349.